JP2001515489A - アモキシシリンナトリウムからなる腸溶性被覆経口剤形 - Google Patents

アモキシシリンナトリウムからなる腸溶性被覆経口剤形

Info

Publication number
JP2001515489A
JP2001515489A JP53949898A JP53949898A JP2001515489A JP 2001515489 A JP2001515489 A JP 2001515489A JP 53949898 A JP53949898 A JP 53949898A JP 53949898 A JP53949898 A JP 53949898A JP 2001515489 A JP2001515489 A JP 2001515489A
Authority
JP
Japan
Prior art keywords
dosage form
enteric
coated
amoxicillin sodium
amoxicillin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP53949898A
Other languages
English (en)
Japanese (ja)
Inventor
ヴェンドシェー，スティーグ
Original Assignee
アストラ・アクチエボラーグ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アストラ・アクチエボラーグ filed Critical アストラ・アクチエボラーグ
Publication of JP2001515489A publication Critical patent/JP2001515489A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP53949898A 1997-03-12 1998-02-27 アモキシシリンナトリウムからなる腸溶性被覆経口剤形 Pending JP2001515489A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9700885A SE9700885D0 (sv) 1997-03-12 1997-03-12 New pharmaceutical formulation
SE9700885-8 1997-03-12
PCT/SE1998/000356 WO1998040054A1 (en) 1997-03-12 1998-02-27 An enteric coated oral dosage form comprising sodium amoxycillin

Publications (1)

Publication Number Publication Date
JP2001515489A true JP2001515489A (ja) 2001-09-18

Family

ID=20406120

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53949898A Pending JP2001515489A (ja) 1997-03-12 1998-02-27 アモキシシリンナトリウムからなる腸溶性被覆経口剤形

Country Status (5)

Country Link
EP (1) EP0981335A1 (de)
JP (1) JP2001515489A (de)
AU (1) AU6426898A (de)
SE (1) SE9700885D0 (de)
WO (1) WO1998040054A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007508351A (ja) * 2003-10-17 2007-04-05 サンド・アクチエンゲゼルシヤフト 抗生物質組成物

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ318282A (en) 1995-09-07 2000-01-28 Smithkline Beecham Corp Pharmaceutical formulation containing amoxycillin and clavulanate in a weight ratio of 12:1 and 20:1
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US7250176B1 (en) 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
ES2202004T3 (es) * 1999-04-13 2004-04-01 Beecham Pharmaceuticals (Pte) Limited Novedoso procedimiento de tratamiento usando un fuerte regimen de dosificacion de amoxicilina y clavulanato potasico.
US6294199B1 (en) * 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
WO2002030392A2 (en) 2000-10-12 2002-04-18 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
GB0031267D0 (en) * 2000-12-21 2001-01-31 Smithkline Beecham Plc Novel compositions
SE0101379D0 (sv) * 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
ES2198195B1 (es) * 2001-12-18 2004-10-01 Laboratorios Del Dr. Esteve, S.A. Forma de dosificacion farmaceutica oral comprimida, con recubrimiento enterico, que contiene un compuesto de bencimidazol labil en medio acido.
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
RU2006132127A (ru) * 2006-09-06 2008-03-20 Государственное Учреждение Научный Центр Здоровьядетей Российской Академии Медицинских Наук (Гу Нцзд Рамн) (Ru) Применение нифуроксазида в качестве компонента комбинированной лекарственной терапии заболеваний, ассоциированных с helicobacter pylori, и способ лечения, направленный на эрадикацию возбудителя
DK2956149T3 (da) 2013-02-13 2019-09-09 Redhill Biopharma Ltd Farmaceutiske sammensætninger til behandling af helicobacter pylori
WO2016112254A1 (en) * 2015-01-09 2016-07-14 The Regents Of The University Of California Compositions and methods for treating gastrointestinal infections
US11878011B2 (en) 2020-05-07 2024-01-23 Redhill Biopharma Ltd. Method for eradicating Helicobacter pylori infection in patients regardless of body mass index

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9201930D0 (sv) * 1992-06-24 1992-06-24 Astra Ab Gastric antibacterial treatment
GB9405856D0 (en) * 1994-03-24 1994-05-11 Smithkline Beecham Plc Pharmaceutical formulation
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007508351A (ja) * 2003-10-17 2007-04-05 サンド・アクチエンゲゼルシヤフト 抗生物質組成物

Also Published As

Publication number Publication date
EP0981335A1 (de) 2000-03-01
WO1998040054A1 (en) 1998-09-17
AU6426898A (en) 1998-09-29
SE9700885D0 (sv) 1997-03-12

Similar Documents

Publication Publication Date Title
EP0754061B1 (de) Neue galenische orale pharmazeutische formulierung
JP2001515489A (ja) アモキシシリンナトリウムからなる腸溶性被覆経口剤形
MXPA96004354A (en) New form of pharmaceutical dosage or
US20040228915A1 (en) Oral extended release compressed tablets of multiparticulates
US9144548B2 (en) Antibiotic product, use and formulation thereof
US8313775B2 (en) Antibiotic product, use and formulation thereof
CA2533178C (en) Antibiotic product, use and formulation thereof
US8425936B2 (en) Antibiotic product, use and formulation thereof
US8246996B2 (en) Antibiotic product, use and formulation thereof
US8460710B2 (en) Antibiotic product, use and formulation thereof
KR100399524B1 (ko) 신규경구제약학상제형